Popular Articles

K2M's ALEUTIAN Spacer Systems Receive FDA Clearance To Be Marketed As Intervertebral Body Fusion Devices
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its ALEUTIAN® Spacer Systems as intervertebral body fusion devices. The ALEUTIAN family of five different systems offers a full array of anatomically designed PEEK-OPTIMA® interbody options, including the Anterior-Lumbar Interbody Fusion (ALIF), Small-Anterior (Cervical), Posterior-Lumbar Interbody Fusion (PLIF), Anatomically Narrow (AN), and Transforaminal-Lumbar Interbody Fusion (TLIF).
generic viagra online
AARP Endorses Bill To Help Americans Get Care In Their Own Homes
More than one million Americans are living in nursing homes, but many would prefer to receive the services they need in their own homes, where they would be more comfortable and potentially save the health care system money in the long run. Unfortunately, many Americans who want to be cared for at home can"t because of a costly institutional bias in Medicaid, which pays for nearly two-thirds of the country"s nursing home residents. While state Medicaid programs are required to provide nursing home care, home and community-based services that are often less expensive are optional, leaving them first in line to be cut in a poor economy.
plastic surgery before after
News of the day
New Five-Question Test Helps Assess Asthma Control In Children Under Five Years Of Age
Caregivers of children under five years of age can now answer five simple questions to determine if their child"s breathing problems are not under control. AstraZeneca funded a research project to create the Test for Respiratory and Asthma Control in Kids, or TRACK, the first validated respiratory- and asthma-control assessment test specifically for patients under five years of age. TRACK helps evaluate respiratory control based on guidelines -- defined asthma impairment and risk.
Medical Devices

Drug Industry Increases Lobbying Efforts And Targets Democrats

The drug industry began ramping up its lobbying efforts in 2003, when Medicare Part D began, and now is targeting Democrats. CQ Politics reports: "The industry is increasingly employing Democratic lobbyists with ties to the Obama administration and congressional leaders such as Sen. Max Baucus, D-Mont., chairman of the Senate Finance Committee. A few years ago, when Republicans controlled Congress and the White House, industry representatives were solidly allied with the GOP. Such efforts might be having an effect. The drug industry sealed a deal recently with Baucus to offer $80 billion in drug discounts for seniors as part of Medicare. The agreement might preempt efforts by liberal Democrats to seek even deeper concessions from the drug industry. The drug companies have opposed a government health insurance component that President Obama and more liberal Democrats are seeking, a provision that could lead to more control over drug prices." CQ Politics notes: "Pharmaceutical manufacturers spent more than any other health care sector on lobbying in the first quarter of this year, shelling out almost $50 million to influence the federal policy making, 17 percent more than they did on average for each quarter of 2008, according to an analysis of lobbying disclosure statements by CQ Moneyline. The industry"s top trade organization, the Pharmaceutical Research & Manufacturers Association (PhRMA), spent $6.9 million during the first three months of this year on lobbying expenses, a 37 percent jump from what it spent on average per quarter last year. Overall the pharmaceutical and drug products industry hired 1,309 lobbyists in the first quarter of this year including three dozen former members of Congress, the Center for Responsive Politics found in an analysis of lobbying disclosure filings. PhRMA has built up an extensive lobbying team that now includes both an in-house staff of at least 26 people and 40 outside firms, according to lobbying disclosure forms filed with Congress ... when it comes to campaign money the industry has clearly been shifting its bucks to Democrats" (Roth, 6/30). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):